Roivant Sciences Ltd. (ROIV) - Investor's Guide

Want to understand Roivant Sciences (ROIV)? Let’s break down their annual report for the year ending March 31, 2026.

Roivant is unique. Instead of developing drugs under one roof, they launch smaller, specialized startups (Vants) for specific medicines. They buy under-valued drug candidates from other firms. If a drug succeeds, Roivant sells the startup or the medicine itself, creating massive paydays for shareholders.

1. The Cash Fortress & Legal Windfalls

Roivant's huge bank account just got a massive boost.

• The Cash Balance: They hold $4.3 billion in cash and short-term investments. This funds operations until they make a profit, avoiding issuing more shares (which reduces your ownership percentage).
• The Moderna Payday: Genevant (83% owned) won a $2.25 billion patent settlement from Moderna. Moderna pays $950 million in July 2026, and $1.3 billion more pending appeal. Partner Arbutus gets a 20% cut ($450 million, leaving Genevant $1.80 billion). For the first payment, Arbutus gets $190 million, leaving Genevant $760 million. For the rest, Arbutus gets $260 million, leaving Genevant $1.04 billion. Roivant's 83% stake captures most of this.
• Next Up, Pfizer? Genevant is suing Pfizer and BioNTech over the same technology. They hold 485 patents running to 2041. Another win could bring billions more.

2. The Next Big Catalysts: Late 2026

Roivant has major milestones coming up:

• Brepocitinib (Priovant - 72% owned): This drug treats a rare, painful inflammatory disease. The FDA will decide on approval in late 2026. Patents protect it until 2035. Approval lets Roivant start selling the drug and generating sales.
• Mosliciguat (Pulmovant - 97% owned): This inhaled lung disease drug has mid-stage trial data coming in late 2026. Patents last until 2042. Good data will prove the drug works before expensive final trials.
• The Pediatric Bonus: Roivant can add six months of monopoly protection to their patents by completing voluntary FDA pediatric studies. This keeps cheaper generic competitors away longer, protecting high profits.

3. The Biotech Rollercoaster: A Major Pivot

Biotech investing is a wild ride, and Roivant shows us why.

• The Failure & Pivot: In April 2026, lead drug batoclimab failed final trials. Roivant immediately shut it down. They shifted all focus to its successor, IMVT-1402. Roivant's multi-startup model let them pivot quickly and limit losses.
• Why IMVT-1402 is Exciting: It showed a strong 72.7% response rate in a rheumatoid arthritis trial. This makes it a potential leader in the autoimmune market. A new patent protects it until 2043 (and potentially 2046), securing decades of sales.

4. What are the Risks?

Keep these risks in mind:

• FDA Hurdles: The FDA can impose strict safety programs that restrict sales and raise costs. Promoting drugs for unapproved uses also brings heavy fines.
• Double Approvals: Some drugs need special diagnostic tests. These tests need separate FDA approvals. If the test is delayed, Roivant cannot sell the drug.
• No Factories: Roivant outsources all manufacturing. If partners fail FDA inspections, drug launches will face delays. Also, Roivant must share profits with partners like Pfizer and Bayer, reducing profit margins.
• Starting from Scratch: Roivant has zero approved products and no sales team. They must build a marketing and sales team from scratch to launch Brepocitinib. This is expensive and pits them against giant rivals.

The Investor's Verdict

Roivant has a great track record with eight FDA approvals since 2014. They have over $4.3 billion in cash, plus a fresh $2.25 billion settlement ($1.80 billion net to Genevant after Arbutus's 20% cut). The batoclimab failure hurts. However, they pivoted quickly to IMVT-1402, which has protection until 2043 or 2046. With an upcoming FDA decision on Brepocitinib and the Pfizer lawsuit, Roivant is an exciting company to watch.